Published 10 days ago • loading... • Updated 9 days ago

InfectoPharm Partners with AudioCure to Advance Hearing Loss Therapy

Summary by World Business Outlook

There is currently no drug approved worldwide for the treatment of sudden hearing loss. However, preclinical and clinical phase-1-studies with the innovative drug candidate AC102 have been promising. AudioCure Pharma, a Berlin-based start-up supported by investors, is driving forward research and development. Now, InfectoPharm, a successful medium-sized company, is joining as a new and essential competence partner. The Heppenheim-based ENT speci…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

World Business Outlook

InfectoPharm Partners with AudioCure to Advance Hearing Loss Therapy

9 days ago

Read Full Article

hearinghealthmatters.org

AudioCure Pharma Secures Funding from InfectoPharm to Accelerate Clinical Trials for AC102 | Hearing Health & Technology Matters

HEPPENHEIM & BERLIN, GERMANY – There is currently no globally approved drug for the treatment of sudden hearing loss, a condition that affects thousands of individuals each year. However, AudioCure Pharma, a Berlin-based biopharmaceutical company, is advancing research on AC102, an innovative drug candidate that has shown promising results in preclinical and Phase 1 clinical studies. In a significant development, InfectoPharm, a Heppenheim-based…

10 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right